Compare IGIC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | MDXG |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 625.6M |
| IPO Year | 2019 | 2007 |
| Metric | IGIC | MDXG |
|---|---|---|
| Price | $24.55 | $4.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $28.00 | $9.00 |
| AVG Volume (30 Days) | 67.1K | ★ 942.2K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $2.54 | $13.02 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $20.82 | $3.03 |
| 52 Week High | $29.59 | $7.97 |
| Indicator | IGIC | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 32.63 | 52.64 |
| Support Level | $24.51 | $4.11 |
| Resistance Level | $25.97 | $4.76 |
| Average True Range (ATR) | 0.58 | 0.19 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 11.43 | 40.68 |
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.